Acquisizione competenze tecnico-professionali:Immune checkpoint blockade (icb) has revolutionized outcomes for patients with advanced cancers. Building upon this marked success, evaluation of icb in patients with surgically resectable disease has been pursued across multiple cancer types. In addition to an improvement in operability, improving the anti-tumor immune response, as measured by pathologic response, neoadjuvant immunotherapy continues to demonstrate correlation with improved risk or recurrence across and has resulted in changes in standard of care. With this in mind, we seek to organize a global meeting to bring together researchers engaged in neoadjuvant immunotherapy clinical and translational research with the goal of highlighting clinical advances, innovative research approaches, as well as possibilities for collaboration and opportunities to harmonize approaches across cancers.